|
1
|
Wu Q, You L, Nepovimova E, Heger Z, Wu W,
Kuca K and Adam V: Hypoxia-inducible factors: Master regulators of
hypoxic tumor immune escape. J Hematol Oncol. 15:772022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao C, Liu X, Zhang C and Zhang Q: Tumor
hypoxia: From basic knowledge to therapeutic implications. Semin
Cancer Biol. 88:172–186. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhuang Y, Liu K, He Q, Gu X, Jiang C and
Wu J: Hypoxia signaling in cancer: Implications for therapeutic
interventions. MedComm (2020). 4:e2032023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wicks EE and Semenza GL: Hypoxia-inducible
factors: Cancer progression and clinical translation. J Clin
Invest. 132:e1598392022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Loboda A, Jozkowicz A and Dulak J: HIF-1
and HIF-2 transcription factors-similar but not identical. Mol
Cells. 29:435–442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
You L, Wu W, Wang X, Fang L, Adam V,
Nepovimova E, Wu Q and Kuca K: The role of hypoxia-inducible factor
1 in tumor immune evasion. Med Res Rev. 41:1622–1643. 2021.
View Article : Google Scholar
|
|
7
|
Palazón A, Martínez-Forero I, Teijeira A,
Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL,
Peñuelas I, Hervás-Stubbs S, Rouzaut A, et al: The HIF-1α hypoxia
response in tumor-infiltrating T lymphocytes induces functional
CD137 (4-1BB) for immunotherapy. Cancer Discov. 2:608–623. 2012.
View Article : Google Scholar
|
|
8
|
Labiano S, Palazón A, Bolaños E,
Azpilikueta A, Sánchez-Paulete AR, Morales-Kastresana A, Quetglas
JI, Perez-Gracia JL, Gúrpide A, Rodriguez-Ruiz M, et al:
Hypoxia-induced soluble CD137 in malignant cells blocks
CD137L-costimulation as an immune escape mechanism. Oncoimmunology.
5:e10629672016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li NA, Wang H, Zhang J and Zhao E:
Knockdown of hypoxia inducible factor-2α inhibits cell invasion via
the downregulation of MMP-2 expression in breast cancer cells.
Oncol Lett. 11:3743–3748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iida H, Suzuki M, Goitsuka R and Ueno H:
Hypoxia induces CD133 expression in human lung cancer cells by
up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79. 2012.
|
|
11
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiong Y, Liu L, Xia Y, Qi Y, Chen Y, Chen
L, Zhang P, Kong Y, Qu Y, Wang Z, et al: Tumor infiltrating mast
cells determine oncogenic HIF-2α-conferred immune evasion in clear
cell renal cell carcinoma. Cancer Immunol Immunother. 68:731–741.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wohlkoenig C, Leithner K, Deutsch A,
Hrzenjak A, Olschewski A and Olschewski H: Hypoxia-induced
cisplatin resistance is reversible and growth rate independent in
lung cancer cells. Cancer Lett. 308:134–143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zub KA, Sousa MM, Sarno A, Sharma A,
Demirovic A, Rao S, Young C, Aas PA, Ericsson I, Sundan A, et al:
Modulation of cell metabolic pathways and oxidative stress
signaling contribute to acquired melphalan resistance in multiple
myeloma cells. PLoS One. 10:e01198572015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Epstein AC, Gleadle JM, McNeill LA,
Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI,
Dhanda A, et al: C. elegans EGL-9 and mammalian homologs define a
family of dioxygenases that regulate HIF by prolyl hydroxylation.
Cell. 107:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruick RK and McKnight SL: A conserved
family of prolyl-4-hydroxylases that modify HIF. Science.
294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ivan M, Kondo K, Yang H, Kim W, Valiando
J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin WG Jr: HIFalpha
targeted for VHL-mediated destruction by proline hydroxylation:
Implications for O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl
hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaelin WG Jr and Ratcliffe PJ: Oxygen
sensing by metazoans: The central role of the HIF hydroxylase
pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semenza GL: Hypoxia-inducible factors in
physiology and medicine. Cell. 148:399–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia X, Lemieux ME, Li W, Carroll JS, Brown
M, Liu XS and Kung AL: Integrative analysis of HIF binding and
transactivation reveals its role in maintaining histone methylation
homeostasis. Proc Natl Acad Sci USA. 106:4260–4265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schödel J, Oikonomopoulos S, Ragoussis J,
Pugh CW, Ratcliffe PJ and Mole DR: High-resolution genome-wide
mapping of HIF-binding sites by ChIP-seq. Blood. 117:e207–217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mole DR, Blancher C, Copley RR, Pollard
PJ, Gleadle JM, Ragoussis J and Ratcliffe PJ: Genome-wide
association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha
DNA binding with expression profiling of hypoxia-inducible
transcripts. J Biol Chem. 284:16767–16775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Warnecke C, Zaborowska Z, Kurreck J,
Erdmann VA, Frei U, Wiesener M and Eckardt KU: Differentiating the
functional role of hypoxia-inducible factor (HIF)-1alpha and
HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin
is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J.
18:1462–1464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fujiwara S, Nakagawa K, Harada H, Nagato
S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S and Ohnishi T:
Silencing hypoxia-inducible factor-1alpha inhibits cell migration
and invasion under hypoxic environment in malignant gliomas. Int J
Oncol. 30:793–802. 2007.PubMed/NCBI
|
|
27
|
Tian H, McKnight SL and Russell DW:
Endothelial PAS domain protein 1 (EPAS1), a transcription factor
selectively expressed in endothelial cells. Genes Dev. 11:72–82.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wiesener MS, Jürgensen JS, Rosenberger C,
Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei
UA, Pugh CW, et al: Widespread hypoxia-inducible expression of
HIF-2alpha in distinct cell populations of different organs. FASEB
J. 17:271–273. 2003. View Article : Google Scholar
|
|
29
|
Raval RR, Lau KW, Tran MG, Sowter HM,
Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe
PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1)
and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol
Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parkin J and Cohen B: An overview of the
immune system. Lancet. 357:1777–1789. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Palazon A, Goldrath AW, Nizet V and
Johnson RS: HIF transcription factors, inflammation, and immunity.
Immunity. 41:518–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peyssonnaux C, Datta V, Cramer T, Doedens
A, Theodorakis EA, Gallo RL, Hurtado-Ziola N, Nizet V and Johnson
RS: HIF-1alpha expression regulates the bactericidal capacity of
phagocytes. J Clin Invest. 115:1806–1815. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cowman SJ and Koh MY: Revisiting the HIF
switch in the tumor and its immune microenvironment. Trends Cancer.
8:28–42. 2022. View Article : Google Scholar
|
|
34
|
Taylor CT and Scholz CC: The effect of HIF
on metabolism and immunity. Nat Rev Nephrol. 18:573–587. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vito A, El-Sayes N and Mossman K:
Hypoxia-Driven Immune Escape in the Tumor Microenvironment. Cells.
9:9922020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liikanen I, Lauhan C, Quon S, Omilusik K,
Phan AT, Bartrolí LB, Ferry A, Goulding J, Chen J, Scott-Browne JP,
et al: Hypoxia-inducible factor activity promotes antitumor
effector function and tissue residency by CD8+ T cells. J Clin
Invest. 131:e1437292021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dhalla NS, Camargo RO, Elimban V, Dhadial
RS and Xu YJ: Role of Skeletal Muscle Angiogenesis in Peripheral
Artery Disease. Biochemical Basis and Therapeutic Implications of
Angiogenesis. 517–532. 2017. View Article : Google Scholar
|
|
38
|
de Heer EC, Jalving M and Harris AL: HIFs,
angiogenesis, and metabolism: Elusive enemies in breast cancer. J
Clin Invest. 130:5074–5087. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Palmer CS, Ostrowski M, Balderson B,
Christian N and Crowe SM: Glucose metabolism regulates T cell
activation, differentiation, and functions. Front Immunol. 6:12015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Menk AV, Scharping NE, Moreci RS, Zeng X,
Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG, et al:
Early TCR signaling induces rapid aerobic glycolysis enabling
distinct acute T cell effector functions. Cell Rep. 22:1509–1521.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang CH, Curtis JD, Maggi LB Jr, Faubert
B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih
J, Qiu J, et al: Posttranscriptional control of T cell effector
function by aerobic glycolysis. Cell. 153:1239–1251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leone RD and Powell JD: Metabolism of
immune cells in cancer. Nat Rev Cancer. 20:516–531. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang R, Dillon CP, Shi LZ, Milasta S,
Carter R, Finkelstein D, McCormick LL, Fitzgerald P, Chi H, Munger
J and Green DR: The transcription factor Myc controls metabolic
reprogramming upon T lymphocyte activation. Immunity. 35:871–882.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Finlay DK, Rosenzweig E, Sinclair LV,
Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K
and Cantrell DA: PDK1 regulation of mTOR and hypoxia-inducible
factor 1 integrate metabolism and migration of CD8+ T cells. J Exp
Med. 209:2441–2453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ohta A, Diwanji R, Kini R, Subramanian M,
Ohta A and Sitkovsky M: In vivo T cell activation in lymphoid
tissues is inhibited in the oxygen-poor microenvironment. Front
Immunol. 2:272011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Byrnes JR, Weeks AM, Shifrut E, Carnevale
J, Kirkemo L, Ashworth A, Marson A and Wells JA: Hypoxia is a
dominant remodeler of the effector T cell surface proteome relative
to activation and regulatory T cell suppression. Mol Cell
Proteomics. 21:1002172022. View Article : Google Scholar
|
|
49
|
Cunha PP, Minogue E, Krause LCM, Hess RM,
Bargiela D, Wadsworth BJ, Barbieri L, Brombach C, Foskolou IP,
Bogeski I, et al: Oxygen levels at the time of activation determine
T cell persistence and immunotherapeutic efficacy. Elife.
12:e842802023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhu X, Chen J, Li W, Xu Y, Shan J, Hong J,
Zhao Y, Xu H, Ma J, Shen J and Qian C: Hypoxia-responsive CAR-T
cells exhibit reduced exhaustion and enhanced efficacy in solid
tumors. Cancer Res. 84:84–100. 2024. View Article : Google Scholar
|
|
51
|
Wang R and Solt LA: Metabolism of murine
TH 17 cells: Impact on cell fate and function. Eur J Immunol.
46:807–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shi LZ, Wang R, Huang G, Vogel P, Neale G,
Green DR and Chi H: HIF1alpha-dependent glycolytic pathway
orchestrates a metabolic checkpoint for the differentiation of TH17
and Treg cells. J Exp Med. 208:1367–1376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Dang EV, Barbi J, Yang HY, Jinasena D, Yu
H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al: Control of
T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell.
146:772–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ivanov II, McKenzie BS, Zhou L, Tadokoro
CE, Lepelley A, Lafaille JJ, Cua DJ and Littman DR: The orphan
nuclear receptor RORgammat directs the differentiation program of
proinflammatory IL-17+ T helper cells. Cell. 126:1121–1133. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Altınönder İ, Kaya M, Yentür SP, Çakar A,
Durmuş H, Yegen G, Özkan B, Parman Y, Sawalha AH and
Saruhan-Direskeneli G: Thymic gene expression analysis reveals a
potential link between HIF-1A and Th17/Treg imbalance in thymoma
associated myasthenia gravis. J Neuroinflammation. 21:1262024.
View Article : Google Scholar
|
|
56
|
Böttcher M, Renner K, Berger R, Mentz K,
Thomas S, Cardenas-Conejo ZE, Dettmer K, Oefner PJ, Mackensen A,
Kreutz M and Mougiakakos D: D-2-hydroxyglutarate interferes with
HIF-1α stability skewing T-cell metabolism towards oxidative
phosphorylation and impairing Th17 polarization. Oncoimmunology.
7:e14454542018. View Article : Google Scholar
|
|
57
|
Clever D, Roychoudhuri R, Constantinides
MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z,
Pan JH, et al: Oxygen sensing by T cells establishes an
immunologically tolerant metastatic niche. Cell. 166:1117–1131.e14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Overacre-Delgoffe AE, Chikina M, Dadey RE,
Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK,
Sander C, et al: Interferon-γ drives Treg fragility to
promote anti-tumor immunity. Cell. 169:1130–1141.e11. 2017.
View Article : Google Scholar
|
|
59
|
Neildez-Nguyen TMA, Bigot J, Da Rocha S,
Corre G, Boisgerault F, Paldi A and Galy A: Hypoxic culture
conditions enhance the generation of regulatory T cells.
Immunology. 144:431–443. 2015. View Article : Google Scholar :
|
|
60
|
Clambey ET, McNamee EN, Westrich JA,
Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC,
Stenmark KR, Colgan SP and Eltzschig HK: Hypoxia-inducible factor-1
alpha-dependent induction of FoxP3 drives regulatory T-cell
abundance and function during inflammatory hypoxia of the mucosa.
Proc Natl Acad Sci USA. 109:E2784–E2793. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wu J, Cui H, Zhu Z, Wang L, Li H and Wang
D: Effect of HIF1α on Foxp3 expression in CD4+ CD25-T lymphocytes.
Microbiol Immunol. 58:409–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hsu TS, Lin YL, Wang YA, Mo ST, Chi PY,
Lai AC, Pan HY, Chang YJ and Lai MZ: HIF-2α is indispensable for
regulatory T cell function. Nat Commun. 11:50052020. View Article : Google Scholar
|
|
63
|
Koh MY and Powis G: Passing the baton: The
HIF switch. Trends Biochem Sci. 37:364–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Palazon A, Tyrakis PA, Macias D, Veliça P,
Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk
I, et al: An HIF-1α/VEGF-A axis in cytotoxic T cells regulates
tumor progression. Cancer Cell. 32:669–683.e5. 2017. View Article : Google Scholar
|
|
65
|
Bisilliat Donnet C, Acolty V, Azouz A,
Taquin A, Henin C, Trusso Cafarello S, Denanglaire S, Mazzone M,
Oldenhove G, Leo O, et al: PHD2 constrains antitumor CD8+ T-cell
activity. Cancer Immunol Res. 11:339–350. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dvorakova T, Finisguerra V, Formenti M,
Loriot A, Boudhan L, Zhu J and Van den Eynde BJ: Enhanced tumor
response to adoptive T cell therapy with PHD2/3-deficient CD8 T
cells. Nat Commun. 15:77892024. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Bargiela D, Cunha PP, Veliça P, Krause
LCM, Brice M, Barbieri L, Gojkovic M, Foskolou IP, Rundqvist H and
Johnson RS: The factor inhibiting HIF regulates T cell
differentiation and anti-tumour efficacy. Front Immunol.
15:12937232024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Walter Jackson I, Yang Y, Salman S, Dordai
D, Lyu Y, Datan E, Drehmer D, Huang TY, Hwang Y and Semenza GL:
Pharmacologic HIF stabilization activates costimulatory receptor
expression to increase antitumor efficacy of adoptive T cell
therapy. Sci Adv. 10:eadq23662024. View Article : Google Scholar
|
|
69
|
Tyrakis PA, Palazon A, Macias D, Lee KL,
Phan AT, Veliça P, You J, Chia GS, Sim J, Doedens A, et al:
S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate.
Nature. 540:236–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lv Q, Su T, Liu W, Wang L, Hu J, Cheng Y,
Ning C, Shan W, Luo X and Chen X: Low serum apolipoprotein A1
levels impair antitumor immunity of CD8+ T cells via the
HIF-1α-glycolysis pathway. Cancer Immunol Res. 12:1058–1073. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Veliça P, Cunha PP, Vojnovic N, Foskolou
IP, Bargiela D, Gojkovic M, Rundqvist H and Johnson RS: Modified
Hypoxia-inducible factor expression in CD8+ T cells
increases antitumor efficacy. Cancer Immunol Res. 9:401–414. 2021.
View Article : Google Scholar
|
|
72
|
Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang
G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, et
al: Enhancing CD8+ T cell fatty acid catabolism within a
metabolically challenging tumor microenvironment increases the
efficacy of melanoma immunotherapy. Cancer Cell. 32:377–391.e9.
2017. View Article : Google Scholar
|
|
73
|
Loisel-Meyer S, Swainson L, Craveiro M,
Oburoglu L, Mongellaz C, Costa C, Martinez M, Cosset FL, Battini
JL, Herzenberg LA, et al: Glut1-mediated glucose transport
regulates HIV infection. Proc Natl Acad Sci USA. 109:2549–2554.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rawlings DJ, Metzler G, Wray-Dutra M and
Jackson SW: Altered B cell signalling in autoimmunity. Nat Rev
Immunol. 17:421–436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Franchina DG, Grusdat M and Brenner D:
B-cell metabolic remodeling and cancer. Trends Cancer. 4:138–150.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Herzog S, Reth M and Jumaa H: Regulation
of B-cell proliferation and differentiation by pre-B-cell receptor
signalling. Nat Rev Immunol. 9:195–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Burrows N, Bashford-Rogers RJM, Bhute VJ,
Peñalver A, Ferdinand JR, Stewart BJ, Smith JEG, Deobagkar-Lele M,
Giudice G, Connor TM, et al: Dynamic regulation of
hypoxia-inducible factor-1α activity is essential for normal B cell
development. Nat Immunol. 21:1408–1420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li S, Huang C, Hu G, Ma J, Chen Y, Zhang
J, Huang Y, Zheng J, Xue W, Xu Y and Zhai W: Tumor-educated B cells
promote renal cancer metastasis via inducing the
IL-1β/HIF-2α/Notch1 signals. Cell Death Dis. 11:1632020. View Article : Google Scholar
|
|
79
|
Zhang F, Li R, Yang Y, Shi C, Shen Y, Lu
C, Chen Y, Zhou W, Lin A, Yu L, et al: Specific decrease in
B-cell-derived extracellular vesicles enhances
post-chemotherapeutic CD8+ T cell responses. Immunity.
50:738–750.e7. 2019. View Article : Google Scholar
|
|
80
|
Ghosh AK, Shanafelt TD, Cimmino A,
Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia
AJ, et al: Aberrant regulation of pVHL levels by microRNA promotes
the HIF/VEGF axis in CLL B cells. Blood. 113:5568–5574. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Jin Z, Xiang R, Dai J, Wang Y and Xu Z:
HIF-1α mediates CXCR4 transcription to activate the AKT/mTOR
signaling pathway and augment the viability and migration of
activated B cell-like diffuse large B-cell lymphoma cells. Mol
Carcinog. 62:676–684. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Gao J, Liang Y and Wang L: Shaping
polarization of tumor-associated macrophages in cancer
immunotherapy. Front Immunol. 13:8887132022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shapouri-Moghaddam A, Mohammadian S,
Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi
A, Afshari JT and Sahebkar A: Macrophage plasticity, polarization,
and function in health and disease. J Cell Physiol. 233:6425–6440.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Anderson NR, Minutolo NG, Gill S and
Klichinsky M: Macrophage-based approaches for cancer immunotherapy.
Cancer Res. 81:1201–1208. 2021. View Article : Google Scholar
|
|
86
|
Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H,
Xiao GG, Rao L and Duo Y: Macrophages in immunoregulation and
therapeutics. Signal Transduct Target Ther. 8:2072023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Takeda N, O'Dea EL, Doedens A, Kim JW,
Weidemann A, Stockmann C, Asagiri M, Simon MC, Hoffmann A and
Johnson RS: Differential activation and antagonistic function of
HIF-{alpha} isoforms in macrophages are essential for NO
homeostasis. Genes Dev. 24:491–501. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang T, Liu H, Lian G, Zhang SY, Wang X
and Jiang C: HIF1α-induced glycolysis metabolism is essential to
the activation of inflammatory macrophages. Mediators Inflamm.
2017:90293272017. View Article : Google Scholar
|
|
89
|
Talks KL, Turley H, Gatter KC, Maxwell PH,
Pugh CW, Ratcliffe PJ and Harris AL: The expression and
distribution of the hypoxia-inducible factors HIF-1alpha and
HIF-2alpha in normal human tissues, cancers, and tumor-associated
macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Leek RD, Talks KL, Pezzella F, Turley H,
Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC and Harris AL:
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha)
expression in tumor-infiltrative macrophages to tumor angiogenesis
and the oxidative thymidine phosphorylase pathway in Human breast
cancer. Cancer Res. 62:1326–1329. 2002.PubMed/NCBI
|
|
91
|
Kawanaka T, Kubo A, Ikushima H, Sano T,
Takegawa Y and Nishitani H: Prognostic significance of HIF-2alpha
expression on tumor infiltrating macrophages in patients with
uterine cervical cancer undergoing radiotherapy. J Med Invest.
55:78–86. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Imtiyaz HZ, Williams EP, Hickey MM, Patel
SA, Durham AC, Yuan LJ, Hammond R, Gimotty PA, Keith B and Simon
MC: Hypoxia-inducible factor 2alpha regulates macrophage function
in mouse models of acute and tumor inflammation. J Clin Invest.
120:2699–2714. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liu N, Luo J, Kuang D, Xu S, Duan Y, Xia
Y, Wei Z, Xie X, Yin B, Chen F, et al: Lactate inhibits ATP6V0d2
expression in tumor-associated macrophages to promote
HIF-2α-mediated tumor progression. J Clin Invest. 129:631–646.
2019. View Article : Google Scholar :
|
|
94
|
Wu JY, Huang TW, Hsieh YT, Wang YF, Yen
CC, Lee GL, Yeh CC, Peng YJ, Kuo YY, Wen HT, et al: Cancer-derived
succinate promotes macrophage polarization and cancer metastasis
via succinate receptor. Mol Cell. 77:213–227.e5. 2020. View Article : Google Scholar
|
|
95
|
Tannahill GM, Curtis AM, Adamik J,
Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ,
Kelly B, Foley NH, et al: Succinate is an inflammatory signal that
induces IL-1β through HIF-1α. Nature. 496:238–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gnarra JR, Tory K, Weng Y, Schmidt L, Wei
MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the
VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:85–90.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Cho H, Du X, Rizzi JP, Liberzon E,
Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA,
et al: On-target efficacy of a HIF-2α antagonist in preclinical
kidney cancer models. Nature. 539:107–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ricketts CJ, Crooks DR and Linehan WM:
Targeting HIF2α in Clear-cell renal cell carcinoma. Cancer Cell.
30:515–517. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chen W, Hill H, Christie A, Kim MS,
Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, et
al: Targeting renal cell carcinoma with a HIF-2 antagonist. Nature.
539:112–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Shen C, Beroukhim R, Schumacher SE, Zhou
J, Chang M, Signoretti S and Kaelin WG Jr: Genetic and functional
studies implicate HIF1α as a 14q kidney cancer suppressor gene.
Cancer Discov. 1:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Cowman SJ, Fuja DG, Liu XD, Tidwell RSS,
Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS,
et al: Macrophage HIF-1α is an independent prognostic indicator in
kidney cancer. Clin Cancer Res. 26:4970–4982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yu Q, Wang Y, Dong L, He Y, Liu R, Yang Q,
Cao Y, Wang Y, Jia A, Bi Y and Liu G: Regulations of glycolytic
activities on macrophages functions in tumor and infectious
inflammation. Front Cell Infect Microbiol. 10:2872020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Pouysségur J, Marchiq I, Parks SK,
Durivault J, Ždralević M and Vucetic M: 'Warburg effect' controls
tumor growth, bacterial, viral infections and immunity-Genetic
deconstruction and therapeutic perspectives. Semin Cancer Biol.
86:334–346. 2022. View Article : Google Scholar
|
|
104
|
Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo
JH, Kim JK, Heo Y, Lee HS, Lee MY, et al: A variant of SLC1A5 is a
mitochondrial glutamine transporter for metabolic reprogramming in
cancer cells. Cell Metab. 31:267–283.e12. 2020. View Article : Google Scholar
|
|
105
|
Green NH, Galvan DL, Badal SS, Chang BH,
LeBleu VS, Long J, Jonasch E and Danesh FR: MTHFD2 links RNA
methylation to metabolic reprogramming in renal cell carcinoma.
Oncogene. 38:6211–6225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Steinberger KJ, Forget MA, Bobko AA,
Mihalik NE, Gencheva M, Roda JM, Cole SL, Mo X, Hoblitzell EH,
Evans R, et al: Hypoxia-inducible factor α subunits regulate
Tie2-expressing macrophages that influence tumor oxygen and
perfusion in murine breast cancer. J Immunol. 205:2301–2311. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Eubank TD, Roda JM, Liu H, O'Neil T and
Marsh CB: Opposing roles for HIF-1α and HIF-2α in the regulation of
angiogenesis by mononuclear phagocytes. Blood. 117:323–332. 2011.
View Article : Google Scholar :
|
|
108
|
Deochand DK, Dacic M, Bale MJ, Daman AW,
Chaudhary V, Josefowicz SZ, Oliver D, Chinenov Y and Rogatsky I:
Mechanisms of epigenomic and functional convergence between
glucocorticoid- and IL4-driven macrophage programming. Nat Commun.
15:90002024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Hara S, Hamada J, Kobayashi C, Kondo Y and
Imura N: Expression and characterization of hypoxia-inducible
factor (HIF)-3alpha in human kidney: Suppression of HIF-mediated
gene expression by HIF-3alpha. Biochem Biophys Res Commun.
287:808–813. 2001. View Article : Google Scholar
|
|
110
|
Wu G, Pan B, Shi H, Yi Y, Zheng X, Ma H,
Zhao M, Zhang Z, Cheng L, Huang Y and Guo W: Neutrophils' dual role
in cancer: From tumor progression to immunotherapeutic potential.
Int Immunopharmacol. 140:1127882024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Qiu B, Yuan P, Du X, Jin H, Du J and Huang
Y: Hypoxia inducible factor-1α is an important regulator of
macrophage biology. Heliyon. 9:e171672023. View Article : Google Scholar
|
|
112
|
Masucci MT, Minopoli M and Carriero MV:
Tumor associated neutrophils. their role in tumorigenesis,
metastasis, prognosis and therapy. Front Oncol. 9:11462019.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2'
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Singhal R, Kotla NK, Solanki S, Huang W,
Bell HN, El-Derany MO, Castillo C and Shah YM: Disruption of
hypoxia-inducible factor-2α in neutrophils decreases
colitis-associated colon cancer. Am J Physiol Gastrointest Liver
Physiol. 326:G53–G66. 2024. View Article : Google Scholar
|
|
115
|
LaGory EL and Giaccia AJ: The
ever-expanding role of HIF in tumour and stromal biology. Nat Cell
Biol. 18:356–365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Santagata S, Ieranò C, Trotta AM,
Capiluongo A, Auletta F, Guardascione G and Scala S: CXCR4 and
CXCR7 signaling pathways: A focus on the Cross-talk between cancer
cells and tumor microenvironment. Front Oncol. 11:5913862021.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lin N and Simon MC: Hypoxia-inducible
factors: Key regulators of myeloid cells during inflammation. J
Clin Invest. 126:3661–3671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Du J, Wang C, Chen Y, Zhong L, Liu X, Xue
L, Zhang Y, Li Y, Li X, Tang C, et al: Targeted downregulation of
HIF-1α for restraining circulating tumor microemboli mediated
metastasis. J Control Release. 343:457–468. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ding XC, Wang LL, Zhang XD, Xu JL, Li PF,
Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al: The relationship
between expression of PD-L1 and HIF-1α in glioma cells under
hypoxia. J Hematol Oncol. 14:922021. View Article : Google Scholar
|
|
120
|
Li J, Xia Y, Sun B, Zheng N, Li Y, Pang X,
Yang F, Zhao X, Ji Z, Yu H, et al: Neutrophil extracellular traps
induced by the hypoxic microenvironment in gastric cancer augment
tumour growth. Cell Commun Signal. 21:862023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Steinman RM: Decisions about dendritic
cells: Past, present, and future. Annu Rev Immunol. 30:1–22. 2012.
View Article : Google Scholar
|
|
122
|
Liu J, Zhang X, Cheng Y and Cao X:
Dendritic cell migration in inflammation and immunity. Cell Mol
Immunol. 18:2461–2471. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
McGettrick AF and O'Neill LAJ: The role of
HIF in immunity and inflammation. Cell Metab. 32:524–536. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Ricciardi A, Elia AR, Cappello P, Puppo M,
Vanni C, Fardin P, Eva A, Munroe D, Wu X, Giovarelli M and Varesio
L: Transcriptome of hypoxic immature dendritic cells: Modulation of
chemokine/receptor expression. Mol Cancer Res. 6:175–185. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Köhler T, Reizis B, Johnson RS, Weighardt
H and Förster I: Influence of hypoxia-inducible factor 1α on
dendritic cell differentiation and migration. Eur J Immunol.
42:1226–1236. 2012. View Article : Google Scholar
|
|
126
|
Liu J, Zhang X, Chen K, Cheng Y, Liu S,
Xia M, Chen Y, Zhu H, Li Z and Cao X: CCR7 chemokine
receptor-inducible lnc-Dpf3 restrains dendritic cell migration by
inhibiting HIF-1α-mediated glycolysis. Immunity. 50:600–615.e15.
2019. View Article : Google Scholar
|
|
127
|
Kim MK and Kim J: Properties of immature
and mature dendritic cells: Phenotype, morphology, phagocytosis,
and migration. RSC Adv. 9:11230–11238. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Kelly B and O'Neill LA: Metabolic
reprogramming in macrophages and dendritic cells in innate
immunity. Cell Res. 25:771–784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Cao L, Wang M, Dong Y, Xu B, Chen J, Ding
Y, Qiu S, Li L, Karamfilova Zaharieva E, Zhou X and Xu Y: Circular
RNA circRNF20 promotes breast cancer tumorigenesis and Warburg
effect through miR-487a/HIF-1α/HK2. Cell Death Dis. 11:1452020.
View Article : Google Scholar
|
|
130
|
Hu Z, Yu X, Ding R, Liu B, Gu C, Pan XW,
Han Q, Zhang Y, Wan J, Cui XG, et al: Glycolysis drives STING
signaling to facilitate dendritic cell antitumor function. J Clin
Invest. 133:e1660312023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Xu K, Yin N, Peng M, Stamatiades EG,
Chhangawala S, Shyu A, Li P, Zhang X, Do MH, Capistrano KJ, et al:
Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support
effector T helper 17 cell responses. Immunity. 54:976–987.e7. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Xu K, Yin N, Peng M, Stamatiades EG, Shyu
A, Li P, Zhang X, Do MH, Wang Z, Capistrano KJ, et al: Glycolysis
fuels phosphoinositide 3-kinase signaling to bolster T cell
immunity. Science. 371:405–410. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Shi R, Tang YQ and Miao H: Metabolism in
tumor microenvironment: Implications for cancer immunotherapy.
MedComm (2020). 1:47–68. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
134
|
O'Neill LA, Kishton RJ and Rathmell J: A
guide to immunometabolism for immunologists. Nat Rev Immunol.
16:553–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Sanmarco LM, Rone JM, Polonio CM,
Fernandez Lahore G, Giovannoni F, Ferrara K, Gutierrez-Vazquez C,
Li N, Sokolovska A, Plasencia A, et al: Lactate limits CNS
autoimmunity by stabilizing HIF-1α in dendritic cells. Nature.
620:881–889. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Gabrilovich D, Ishida T, Oyama T, Ran S,
Kravtsov V, Nadaf S and Carbone DP: Vascular endothelial growth
factor inhibits the development of dendritic cells and dramatically
affects the differentiation of multiple hematopoietic lineages in
vivo. Blood. 92:4150–4166. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gabrilovich DI, Chen HL, Girgis KR,
Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Noman MZ, Hasmim M, Messai Y, Terry S,
Kieda C, Janji B and Chouaib S: Hypoxia: A key player in antitumor
immune response. A review in the theme: Cellular responses to
hypoxia. Am J Physiol Cell Physiol. 309:C569–C579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Baginska J, Viry E, Paggetti J, Medves S,
Berchem G, Moussay E and Janji B: The critical role of the tumor
microenvironment in shaping natural killer cell-mediated anti-tumor
immunity. Front Immunol. 4:4902013. View Article : Google Scholar
|
|
141
|
Barsoum IB, Hamilton TK, Li X, Cotechini
T, Miles EA, Siemens DR and Graham CH: Hypoxia induces escape from
innate immunity in cancer cells via increased expression of ADAM10:
Role of nitric oxide. Cancer Res. 71:7433–7441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Ni J, Wang X, Stojanovic A, Zhang Q,
Wincher M, Bühler L, Arnold A, Correia MP, Winkler M, Koch PS, et
al: Single-cell RNA sequencing of tumor-infiltrating NK cells
reveals that inhibition of transcription factor HIF-1α unleashes NK
cell activity. Immunity. 52:1075–1087.e8. 2020. View Article : Google Scholar
|
|
143
|
Nakazawa T, Morimoto T, Maeoka R, Yamada
K, Matsuda R, Nakamura M, Nishimura F, Yamada S, Park YS, Tsujimura
T and Nakagawa I: Characterization of HIF-1α knockout primary human
natural killer cells including populations in allogeneic
glioblastoma. Int J Mol Sci. 25:58962024. View Article : Google Scholar
|
|
144
|
Cluff E, Magdaleno CC, Fernandez E, House
T, Swaminathan S, Varadaraj A and Rajasekaran N: Hypoxia-inducible
factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR
pathway in hypoxic NK cells and supports effector functions in NKL
cells and ex vivo expanded NK cells. Cancer Immunol Immunother.
71:1989–2005. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Heikkilä M, Pasanen A, Kivirikko KI and
Myllyharju J: Roles of the human hypoxia-inducible factor (HIF)-3α
variants in the hypoxia response. Cell Mol Life Sci. 68:3885–3901.
2011. View Article : Google Scholar
|
|
146
|
Kummar S, Chen A, Ji J, Zhang Y, Reid JM,
Ames M, Jia L, Weil M, Speranza G, Murgo AJ, et al: Phase I study
of PARP inhibitor ABT-888 in combination with topotecan in adults
with refractory solid tumors and lymphomas. Cancer Res.
71:5626–5634. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Jonasch E, Donskov F, Iliopoulos O,
Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie
JK, Welsh SJ, et al: Belzutifan for renal cell carcinoma in von
Hippel-Lindau disease. N Engl J Med. 385:2036–2046. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Cheng B, Ma X, Zhou Y, Liu J, Fei X, Pan
W, Peng X, Wang W and Chen J: Recent progress in the development of
hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors,
agonists, and degraders (2009-2024). Eur J Med Chem.
275:1166452024. View Article : Google Scholar
|
|
149
|
Wu H, Zhao X, Hochrein SM, Eckstein M,
Gubert GF, Knöpper K, Mansilla AM, Öner A, Doucet-Ladevèze R,
Schmitz W, et al: Mitochondrial dysfunction promotes the transition
of precursor to terminally exhausted T cells through
HIF-1α-mediated glycolytic reprogramming. Nat Commun. 14:68582023.
View Article : Google Scholar
|
|
150
|
Jiao X, Zhang Y, Li W, Zhou X, Chu W, Li
Y, Wang Z, Sun X, Xu C and Gan Y: HIF-1α inhibition attenuates
severity of Achilles tendinopathy by blocking NF-κB and MAPK
pathways. Int Immunopharmacol. 106:1085432022. View Article : Google Scholar
|
|
151
|
Taylor CT, Doherty G, Fallon PG and
Cummins EP: Hypoxia-dependent regulation of inflammatory pathways
in immune cells. J Clin Invest. 126:3716–3724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Li Z, Cheng G, Zhang Q, Wu W, Zhang Y, Wu
B, Liu Z, Tong X, Xiao B, Cheng L and Dai F: PX478-loaded silk
fibroin nanoparticles reverse multidrug resistance by inhibiting
the hypoxia-inducible factor. Int J Biol Macromol. 222:2309–2317.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Tiwari H, Rai N, Singh S, Gupta P, Verma
A, Singh AK, Kajal, Salvi P, Singh SK, Gautam V, et al: Recent
advances in Nanomaterials-based targeted drug delivery for
preclinical cancer diagnosis and therapeutics. Bioengineering
(Basel). 10:7602023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Park K, Lee HE, Lee SH, Lee D, Lee T and
Lee YM: Molecular and functional evaluation of a novel HIF
inhibitor, benzopyranyl 1,2,3-triazole compound. Oncotarget.
8:7801–7813. 2017. View Article : Google Scholar :
|
|
155
|
Wang Z, Wu J, Humphries B, Kondo K, Jiang
Y, Shi X and Yang C: Upregulation of Histone-lysine
methyltransferases plays a causal role in hexavalent
chromium-induced cancer stem Cell-like property and cell
transformation. Toxicol Appl Pharmacol. 342:22–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Spera D, Siciliano T, De Tommasi N, Braca
A and Vessières A: Antiproliferative cardenolides from Periploca
graeca. Planta Med. 73:384–387. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Sapra P, Kraft P, Mehlig M, Malaby J, Zhao
H, Greenberger LM and Horak ID: Marked therapeutic efficacy of a
novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft
models of B-cell non-Hodgkin's lymphoma. Haematologica.
94:1456–1459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Sapra P, Zhao H, Mehlig M, Malaby J, Kraft
P, Longley C, Greenberger LM and Horak ID: Novel delivery of SN38
markedly inhibits tumor growth in xenografts, including a
camptothecin-11-refractory model. Clin Cancer Res. 14:1888–1896.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Ban HS, Kim BK, Lee H, Kim HM, Harmalkar
D, Nam M, Park SK, Lee K, Park JT, Kim I, et al: The novel
hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer
metabolism, thereby suppressing tumor growth. Cell Death Dis.
8:e28432017. View Article : Google Scholar
|
|
160
|
Wang L, Syn NL, Subhash VV, Any Y, Thuya
WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, et al: Pan-HDAC
inhibition by panobinostat mediates chemosensitization to
carboplatin in non-small cell lung cancer via attenuation of EGFR
signaling. Cancer Lett. 417:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Lee WY, Chen PC, Wu WS, Wu HC, Lan CH,
Huang YH, Cheng CH, Chen KC and Lin CW: Panobinostat sensitizes
KRAS-mutant non-small-cell lung cancer to gefitinib by targeting
TAZ. Int J Cancer. 141:1921–1931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Bali P, Pranpat M, Swaby R, Fiskus W,
Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V and Bhalla K:
Activity of suberoylanilide hydroxamic Acid against human breast
cancer cells with amplification of her-2. Clin Cancer Res.
11:6382–6389. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Kim KH, Kim D, Park JY, Jung HJ, Cho YH,
Kim HK, Han J, Choi KY and Kwon HJ: NNC 55-0396, a T-type Ca2+
channel inhibitor, inhibits angiogenesis via suppression of
hypoxia-inducible factor-1α signal transduction. J Mol Med (Berl).
93:499–509. 2015. View Article : Google Scholar
|
|
164
|
Courtney KD, Infante JR, Lam ET, Figlin
RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace
EM, et al: Phase I Dose-escalation trial of PT2385, a
first-in-class hypoxia-inducible factor-2α antagonist in patients
with previously treated advanced clear cell renal cell carcinoma. J
Clin Oncol. 36:867–874. 2018. View Article : Google Scholar
|
|
165
|
Courtney KD, Ma Y, Diaz de Leon A,
Christie A, Xie Z, Woolford L, Singla N, Joyce A, Hill H,
Madhuranthakam AJ, et al: HIF-2 complex dissociation, target
inhibition, and acquired resistance with PT2385, a First-in-class
HIF-2 inhibitor, in patients with clear cell renal cell carcinoma.
Clin Cancer Res. 26:793–803. 2020. View Article : Google Scholar
|
|
166
|
Ma Y, Joyce A, Brandenburg O, Saatchi F,
Stevens C, Toffessi Tcheuyap V, Christie A, Do QN, Fatunde O,
Macchiaroli A, et al: HIF2 inactivation and tumor suppression with
a Tumor-Directed RNA-silencing drug in mice and humans. Clin Cancer
Res. 28:5405–5418. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Keefe SM, Hoffman-Censits J, Cohen RB,
Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG,
Gunnarsson O, et al: Efficacy of the nanoparticle-drug conjugate
CRLX101 in combination with bevacizumab in metastatic renal cell
carcinoma: Results of an investigator-initiated phase I-IIa
clinical trial. Ann Oncol. 27:1579–1585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Huang YC, Huang FI, Mehndiratta S, Lai SC,
Liou JP and Yang CR: Anticancer activity of MPT0G157, a derivative
of indolylbenzenesulfonamide, inhibits tumor growth and
angiogenesis. Oncotarget. 6:18590–18601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Lee S, Kwon OS, Lee CS, Won M, Ban HS and
Ra CS: Synthesis and biological evaluation of kresoxim-methyl
analogues as novel inhibitors of hypoxia-inducible factor (HIF)-1
accumulation in cancer cells. Bioorg Med Chem Lett. 27:3026–3029.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Lecomte S, Chalmel F, Ferriere F,
Percevault F, Plu N, Saligaut C, Surel C, Lelong M, Efstathiou T
and Pakdel F: Glyceollins trigger anti-proliferative effects
through estradiol-dependent and independent pathways in breast
cancer cells. Cell Commun Signal. 15:262017. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Palayoor ST, Mitchell JB, Cerna D, Degraff
W, John-Aryankalayil M and Coleman CN: PX-478, an inhibitor of
hypoxia-inducible factor-1alpha, enhances radiosensitivity of
prostate carcinoma cells. Int J Cancer. 123:2430–2437. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Piorecka K, Kurjata J and Stanczyk WA:
Acriflavine, an acridine derivative for biomedical application:
Current state of the art. J Med Chem. 65:11415–11432. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Baker LC, Boult JK, Walker-Samuel S, Chung
YL, Jamin Y, Ashcroft M and Robinson SP: The HIF-pathway inhibitor
NSC-134754 induces metabolic changes and anti-tumour activity while
maintaining vascular function. Br J Cancer. 106:1638–1647. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Mabjeesh NJ, Escuin D, LaVallee TM,
Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW
and Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by
disrupting microtubules and dysregulating HIF. Cancer Cell.
3:363–375. 2003. View Article : Google Scholar : PubMed/NCBI
|
